DAVID MYERS: Open Payments
NPI 1598816696 · METAIRIE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$631 in 16 payments from 11 companies in 2025. Trend: 2023 $909 · 2024 $641 · 2025 $631
Food & beverage: $631
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 1 | $125 |
| Novo Nordisk Inc | 1 | $125 |
| Eisai Inc. | 1 | $113 |
| AstraZeneca Pharmaceuticals LP | 5 | $87 |
| Lilly USA, LLC | 2 | $42 |
| UCB, Inc. | 1 | $30 |
| Aimmune Therapeutics, Inc. | 1 | $29 |
| Lundbeck LLC | 1 | $27 |
| Esperion Therapeutics, Inc. | 1 | $21 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $17 |
Products named: Yeztugo, Ozempic, Leqembi, FARXIGA, MOUNJARO, BREZTRI, Nayzilam, ZENPEP.
Industry payments across LA — which companies pay providers there.
